Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The role if follistatin in HIV-associated pre-eclampsia

14th World Congress on Infection Prevention and Control

Siphesihle Mdlalose, Jagedisa Moodley and Thajasvarie Naicker

Department of Optics and Imaging, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.Womens Health and HIV Studies, Department of Obstetrics and Gynaecology, Nelson Mandela School of Medicine, College of Health Sciences, Universityof KwaZulu-Natal, Durban, South

Posters & Accepted Abstracts: J Infect Dis Ther

DOI: 10.4172/2332-0877-C6-054

Abstract
KwaZulu-Natal has a high burden of HIV infection and high blood pressure, specifically pre-eclampsia (PE) in pregnancy. Follistatin (FS) is an extracellular glycoprotein antagonist of the ligand receptor, Activin-A, involved in PE pathogenesis. In light of the high maternal mortality and morbidity in SA, we investigated the expression of FS in the duality of HIVassociated PE. Therefore, the aim of this study was to investigate the role of FS in HIV-associated PE using the Bioplex Multiplex Immunoassay. The methodology used -serum samples of normotensive and pre-eclamptic women stratified by HIV status were collected from a large regional hospital in Durban, and their FS expression was analysed using the Bio-Plex® Pro™ Human Cancer Biomarker Panel 1. Our results revealed that irrespective of HIV status, FS expression was significantly reduced in pre-eclamptic compared to normotensive pregnancies (2354±353.6 vs 649.5±116.8; p<0.001). However, FS expression did not differ between HIV +ve vs HIV –ve groups (1727±291.2 vs 1305±306.7; p=0.13)- regardless of pregnancy type. Furthermore, we detected significant FS expression across all study groups (p<0.05). In conclusion, this study demonstrates a downregulation of FS expression in PE, possibly due to oxidative stress and its immunoregulatory role in the hyperinflammatory milieu of PE. Moreover, the fact that FS did not vary by HIV status may be attributed to the effects of HAART regimen adopted in SA. It is also plausible to assume that the upregulation of FS expression (albeit non-significant) in HIV +ve patients, arises as a result of the immune response in controlling viral infection. Our novel findings suggest that FS may have a potential predicator test value early in pregnancy, hence work on this is ongoing.
Biography

E-mail: sphemdlalose0@gmail.com

 

Top